Moderna

Moderna has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. Stéphane Bancel, Chief Executive Officer of Moderna, said: “We look forward to working with the FDA […]

Moderna has announced that its Phase II/III study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants who had received two doses of the Moderna Covid-19 vaccine. In addition, a vaccine efficacy […]

The UK government has begun the Cov-Boost clinical trials for a booster coronavirus vaccine in a bid to test its effectiveness against the new variants of the virus. As part of the trial, seven vaccines ordered by the UK government will be tested on thousands of volunteers at random in all age groups to see […]

Moderna has announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the Covid-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. Through this agreement, on behalf of the COVAX Facility, Gavi also retains the option to procure 466 million […]

Moderna is to increase supply at its manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its Covid-19 vaccine. This will depend upon the mix between the authorised Moderna Covid-19 vaccine at the 100 μg dose level and potentially lower doses of the company’s variant booster candidates […]

Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through six months following the second dose of our Covid-19 vaccine,” said […]

Moderna has announced that the first participants have been dosed in the Phase II/II study, called the KidCOVE study, of mRNA-1273, the company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National […]

Moderna has announced that the first participants have been dosed in the Phase I study of mRNA-1283, the company’s next generation COVID-19 vaccine candidate. mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers Stéphane Bancel, Chief Executive Officer of Moderna, said: “Our investments […]

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been identified, the B.1.1.7 variant is […]